Clinical Trials Logo

Filter by:
NCT ID: NCT00332202 Completed - Clinical trials for Non Hodgkin Lymphoma

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Start date: June 2006
Phase: Phase 3
Study type: Interventional

This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.

NCT ID: NCT00331149 Completed - Parkinson Disease Clinical Trials

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

Start date: June 20, 2006
Phase: Phase 3
Study type: Interventional

This study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries. The new prolonged release formulation allows the drug to be taken once a day rather than three times a day. This study will also evaluate the side effects of the new prolonged release formulation of ropinirole

NCT ID: NCT00329628 Completed - Clinical trials for Venous Thromboembolism

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Start date: February 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.

NCT ID: NCT00329238 Completed - Thromboembolism Clinical Trials

Secondary Prevention of Venous Thrombo Embolism (VTE).

RE-MEDY
Start date: May 2006
Phase: Phase 3
Study type: Interventional

The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.

NCT ID: NCT00327535 Completed - Anemia Clinical Trials

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This 4 arm study will assess the optimal starting dose of Mircera in the treatment of anemia in patients with non-small cell lung cancer receiving first line myelosuppressive chemotherapy. Patients will be randomized to receive either Mircera 6.3 micrograms/kg, 9 micrograms/kg or 12 micrograms/kg s.c. every 3 weeks or darbepoetin alfa according to the approved local label (either 6.75 micrograms/kg s.c. every 3 weeks, or 2.25 micrograms/kg every week). The anticipated time on study treatment is <3 months and the target sample size is 100-500 individuals.

NCT ID: NCT00327444 Completed - Ovarian Neoplasms Clinical Trials

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Start date: July 2006
Phase: Phase 2/Phase 3
Study type: Interventional

This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancer Secondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.

NCT ID: NCT00327015 Completed - Diabetes Clinical Trials

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Start date: May 2006
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone

NCT ID: NCT00326248 Completed - Clinical trials for Nausea and Vomiting, Postoperative

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Start date: March 2006
Phase: Phase 3
Study type: Interventional

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

NCT ID: NCT00326001 Completed - Atrial Flutter Clinical Trials

Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8)

Start date: June 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate the advantage of using a gold alloy tip electrode over a platinum/iridium alloy tip electrode in ablation of the cavotricuspid isthmus in patients with atrial flutter.

NCT ID: NCT00325364 Completed - Clinical trials for Diabetes Mellitus, Type 2

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

Start date: April 2006
Phase: Phase 3
Study type: Interventional

This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 2 diabetes. Patients will be treated for 24 months with a 2-month follow-up period.